Cantor Fitzgerald Comments on KROS FY2025 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Keros Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($5.82) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.33) EPS.

Several other research analysts also recently issued reports on the company. Jefferies Financial Group began coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Oppenheimer decreased their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Wells Fargo & Company lifted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Finally, Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and an average price target of $52.56.

Keros Therapeutics Trading Up 5.1 %

Keros Therapeutics stock opened at $11.41 on Wednesday. The stock has a 50-day moving average price of $35.23 and a two-hundred day moving average price of $46.97. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The company has a market capitalization of $462.18 million, a PE ratio of -2.19 and a beta of 1.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. grew its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the period. Alkeon Capital Management LLC grew its holdings in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares during the period. Parkman Healthcare Partners LLC increased its stake in Keros Therapeutics by 112.3% in the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after purchasing an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Keros Therapeutics by 814.6% during the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after purchasing an additional 199,245 shares during the period. Finally, FMR LLC boosted its position in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.